Jury rules in favor of Gilead Sciences in HIV prevention treatment patent case.

A Delaware jury has ruled that Gilead Sciences did not violate patents held by the Centers for Disease and Prevention on an HIV prevention drug. The US government had sued Gilead in 2019, alleging that the company was profiting off CDC patents through the sales of Truvada and Descovy. The jury found that the government's patent claims on an HIV prevention regimen called pre-exposure prophylaxis, or PrEP, were not valid after a multiday trial in federal court.